MedTrace Logo

ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan

NCT00158548 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 650

Last updated 2017-01-12

No results posted yet for this study

Summary

Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it is critical to preserve the effective life of SP by using it in combination with artesunate. Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.

Conditions

  • Malaria
  • Falciparum Malaria
  • Vivax Malaria

Interventions

DRUG

SP, chloroquine, amodiaquine, primaquine, artesunate

Sponsors & Collaborators

  • World Health Organization

    collaborator OTHER

  • HealthNet TPO

    collaborator OTHER

  • United Nations High Commissioner for Refugees

    collaborator OTHER

  • Malaria Control Program, Directorate of Malaria Control, Pakistan

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Kate Graham, MSc · HealthNet International, Peshawar, Pakistan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Completion
2004-12-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00158548 on ClinicalTrials.gov